Cargando…

Treatment of Osteofibrous Dysplasia and Associated Lesions

PURPOSE: To report long term treatment outcomes of osteofibrous dysplasia and association with adamantinoma. PATIENTS AND METHODS: From January 1984 to July 2001, 14 patients with osteofibrous dysplasia were followed for an average of 108 months (78 to 260 months). Our patient group consisted of 6 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Soo Bong, Kim, Sung Hun, Cho, Nam Hoon, Choi, Chul Jun, Kim, Bom Soo, Kang, Ho Jung
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628088/
https://www.ncbi.nlm.nih.gov/pubmed/17594160
http://dx.doi.org/10.3349/ymj.2007.48.3.502
_version_ 1782163656803352576
author Hahn, Soo Bong
Kim, Sung Hun
Cho, Nam Hoon
Choi, Chul Jun
Kim, Bom Soo
Kang, Ho Jung
author_facet Hahn, Soo Bong
Kim, Sung Hun
Cho, Nam Hoon
Choi, Chul Jun
Kim, Bom Soo
Kang, Ho Jung
author_sort Hahn, Soo Bong
collection PubMed
description PURPOSE: To report long term treatment outcomes of osteofibrous dysplasia and association with adamantinoma. PATIENTS AND METHODS: From January 1984 to July 2001, 14 patients with osteofibrous dysplasia were followed for an average of 108 months (78 to 260 months). Our patient group consisted of 6 men and 8 women, with a mean age of 13.9 years (2 to 65 years). We reviewed the clinical and pathological features of all 14 patients. RESULTS: Thirteen patients had a lesion in the tibia, while one patient had lesions in both the tibia and the fibula. Initial treatments were observation after biopsy (6 patients), curettage with or without a bone graft (3 patients), resection followed by a free vascularized fibular bone graft (4 patients), or resection and regeneration with the Ilizarov external fixation (1 patient). Curettage was performed on 6 patients due to recurrence or progression after the initial treatment. Among these patients, one was diagnosed with AD from the biopsy of the recurrent lesion. This patient was further treated by segmental resection and pasteurization. After the initial pathology slides of the 13 patients were reviewed with immunohistochemical cytokeratin staining, one patient diagnosis was changed from osteofibrous dysplasia to osteofibrous dysplasia-like adamantinoma. CONCLUSION: Some patients with osteofibrous dysplasia require close observation because of the high association risk between osteofibrous dysplasia and adamantinoma, Immunohistochemical staining may be helpful in differentiating these two diagnoses.
format Text
id pubmed-2628088
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-26280882009-02-02 Treatment of Osteofibrous Dysplasia and Associated Lesions Hahn, Soo Bong Kim, Sung Hun Cho, Nam Hoon Choi, Chul Jun Kim, Bom Soo Kang, Ho Jung Yonsei Med J Original Article PURPOSE: To report long term treatment outcomes of osteofibrous dysplasia and association with adamantinoma. PATIENTS AND METHODS: From January 1984 to July 2001, 14 patients with osteofibrous dysplasia were followed for an average of 108 months (78 to 260 months). Our patient group consisted of 6 men and 8 women, with a mean age of 13.9 years (2 to 65 years). We reviewed the clinical and pathological features of all 14 patients. RESULTS: Thirteen patients had a lesion in the tibia, while one patient had lesions in both the tibia and the fibula. Initial treatments were observation after biopsy (6 patients), curettage with or without a bone graft (3 patients), resection followed by a free vascularized fibular bone graft (4 patients), or resection and regeneration with the Ilizarov external fixation (1 patient). Curettage was performed on 6 patients due to recurrence or progression after the initial treatment. Among these patients, one was diagnosed with AD from the biopsy of the recurrent lesion. This patient was further treated by segmental resection and pasteurization. After the initial pathology slides of the 13 patients were reviewed with immunohistochemical cytokeratin staining, one patient diagnosis was changed from osteofibrous dysplasia to osteofibrous dysplasia-like adamantinoma. CONCLUSION: Some patients with osteofibrous dysplasia require close observation because of the high association risk between osteofibrous dysplasia and adamantinoma, Immunohistochemical staining may be helpful in differentiating these two diagnoses. Yonsei University College of Medicine 2007-06-30 2007-06-20 /pmc/articles/PMC2628088/ /pubmed/17594160 http://dx.doi.org/10.3349/ymj.2007.48.3.502 Text en Copyright © 2007 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hahn, Soo Bong
Kim, Sung Hun
Cho, Nam Hoon
Choi, Chul Jun
Kim, Bom Soo
Kang, Ho Jung
Treatment of Osteofibrous Dysplasia and Associated Lesions
title Treatment of Osteofibrous Dysplasia and Associated Lesions
title_full Treatment of Osteofibrous Dysplasia and Associated Lesions
title_fullStr Treatment of Osteofibrous Dysplasia and Associated Lesions
title_full_unstemmed Treatment of Osteofibrous Dysplasia and Associated Lesions
title_short Treatment of Osteofibrous Dysplasia and Associated Lesions
title_sort treatment of osteofibrous dysplasia and associated lesions
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628088/
https://www.ncbi.nlm.nih.gov/pubmed/17594160
http://dx.doi.org/10.3349/ymj.2007.48.3.502
work_keys_str_mv AT hahnsoobong treatmentofosteofibrousdysplasiaandassociatedlesions
AT kimsunghun treatmentofosteofibrousdysplasiaandassociatedlesions
AT chonamhoon treatmentofosteofibrousdysplasiaandassociatedlesions
AT choichuljun treatmentofosteofibrousdysplasiaandassociatedlesions
AT kimbomsoo treatmentofosteofibrousdysplasiaandassociatedlesions
AT kanghojung treatmentofosteofibrousdysplasiaandassociatedlesions